ClinicaliQ Trial Snapshot
- Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis — Active Not Recruiting • Phase III • NCT05556096.
- ALXN1720 (a complement inhibitor) was tested for safety and effectiveness in treating autoimmune myasthenia gravis in adults.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this study is to evaluate the safety and efficacy of ALXN1720 for the treatment of generalized MG (gMG) in adults with autoantibodies against acetylcholine receptor (AChR). Conditions: Generalized Myasthenia Gravis Interventions: ALXN1720, Placebo Lead Sponsor: Alexion Pharmaceuticals, Inc. Planned Enrollment: 261 participants